文献速递前列腺癌

F-18-PSMA-1007 PET在前列腺癌原发分期中的评估:与多参数MRI及组织病理学的比较

Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-09-30

结果显示PET对精囊侵犯(pT3b)分期正确率高于mpMRI(90% vs 76%),而mpMRI对包膜外侵犯(pT3a)更准确(90% vs 57%)。

要点

  • F-18-PSMA-1007 PET/CT对精囊侵犯(pT3b)分期正确率高于mpMRI(90% vs 76%)。
  • mpMRI对包膜外侵犯(pT3a)检测准确性优于F-18-PSMA-1007 PET(90% vs 57%)。
  • F-18-PSMA-1007肾脏清除率低,有助于评估膀胱邻近肿瘤。

核心结论

  • 在选定队列中,mpMRI与F-18-PSMA-1007 PET双影像可能改善原发性前列腺癌的分期。

主要发现

  • 共识别66个可疑mpMRI病灶并进行了MR引导靶向活检。
  • 2个病灶的最大标准化摄取值(SUVmax)低于健康前列腺组织的平均SUVmax,被视为非PSMA表达。
  • 所有PSMA avid肿瘤的SUVmax均高于膀胱/尿液的平均SUVmean,因此所有病灶在盆腔区域均可清晰区分。
  • F-18-PSMA-1007 PET/CT对精囊侵犯(pT3b)分期正确率高于mpMRI(90% vs 76%)。
  • mpMRI对包膜外侵犯(pT3a)检测准确性高于F-18-PSMA-1007 PET(90% vs 57%)。

临床怎么用

  • 对于中高危前列腺癌患者,可考虑mpMRI与F-18-PSMA-1007 PET双影像以改善原发分期。
  • F-18-PSMA-1007 PET/CT肾脏清除率低,可能有助于评估膀胱邻近肿瘤。

局限性

  • 本研究为回顾性研究,且为选定队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PSMA-PET is a novel imaging modality for the staging of prostate cancer (PCa). While there are several PSMA ligands available, F-18-PSMA-1007 is particularly of interest as it is not renally excreted and therefore does not impair the imaging of the pelvic area. Hence, this study aimed to investigate the F-18-PSMA-1007-PET for the primary staging of PCa and compared it to multi-parametric (mp) MRI and histopathology. METHODS: A retrospective study was performed of men with intermediate and high-risk PCa patients that underwent a F-18-PSMA-1007-PET after mpMRI with subsequent MR-guided target biopsy (MRGB). Suspicious mpMRI lesions and F-18-PSMA-1007-PET were simultaneously reviewed on both a per patient and per-lesion basis. Results were subsequently evaluated with histopathological outcome of MRGB, and if performed, the radical prostatectomy specimen. RESULTS: A total of 66 suspicious mpMRI lesions were identified in 53 patients and underwent MRGB. Two lesions had a maximum standardized uptake value (SUVmax) less than the mean SUVmax of healthy prostate tissue and were considered as non-PSMA-expressing. All PSMA avid tumors had higher SUVmax than the mean SUVmean of the bladder/urine, therefore all lesions were clearly distinguishable in the pelvic area. Twenty-three patients received a radical prostatectomy of which the histopathology specimens were evaluated. F-18-PSMA-1007-PET/CT correctly staged seminal vesicle invasion (i.e. pT3b) more often than mpMRI (90 vs. 76%), whereas mpMRI more accurately detected extracapsular extension (i.e. pT3a) compared to F-18-PSMA-1007-PET (90% vs 57%). CONCLUSIONS: The present study of a selected cohort suggest that dual imaging with mpMRI and F-18-PSMA-1007-PET may improve staging of primary PCa. F-18-PSMA-1007-PET/CT had low renal clearance, which could assist the evaluation of tumors in proximity of the bladder.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Privé BM, Israël B, Schilham MGM, et al. Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. Prostate Cancer Prostatic Dis. 2020. PMID: 32999466. doi:10.1038/s41391-020-00292-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。